BrainAurora Medical Technology Issues Clarification on Annual Report: Pre-IPO Share Award Scheme Details Corrected

Key Points for Investors

• Clarification Announcement: BrainAurora Medical Technology Limited (Stock Code: 6681) has issued an official clarification regarding its Annual Report for the year ended December 31, 2025. This announcement addresses inadvertent clerical errors found in the “Date of grant” column relating to the Pre-IPO Share Award Scheme.
• Share Award Scheme Details Corrected: The company has provided an amended table listing the accurate dates and numbers of shares granted to directors, substantial shareholders, and other employees under the Pre-IPO Share Award Scheme.
• Directors and Substantial Shareholders: The correction primarily affects the reported share awards to key management and substantial shareholders, notably Mr. Tan (Executive Director), Dr. Wang (resigned effective June 19, 2025), and Mr. Cai Longjun (appointed CEO on November 18, 2025).
• Impact on Share Subdivision: Following the share subdivision and global offering, each awarded share was split into 1,000 shares, significantly increasing the total number of shares underlying the awards.
• Total Awarded Shares: 85,166,000 shares were outstanding as of December 31, 2025, representing 6.73% of the issued shares. This is a substantial figure, particularly for investors monitoring dilution or insider holdings.
• Vesting Schedule: The awarded shares vest in three tranches: 30% on the first anniversary of listing, 30% on the second, and 40% on the third. This structured vesting could have implications for future sell-downs or share price movements as tranches vest.
• Special Cases: Dr. Wang, despite resigning from executive roles, remains a consultant and retains his awarded shares, which are not forfeited. Some shares previously allocated to employees who left the company have been re-allocated to other selected employees.
• Board Composition Update: As of the announcement date, executive, non-executive, and independent directors are listed, with new appointments highlighted.

Important Information for Shareholders

• Correction of Clerical Errors: The clarification ensures investors and shareholders have accurate information regarding the timing and allocation of share awards. Incorrect reporting of such details could have led to misunderstandings regarding insider holdings and potential dilution.
• Potential Price Sensitivity:
  • Large Insider Holdings: The substantial number of shares awarded to management and key employees (over 6.7% of issued shares) may be price sensitive, especially as vesting periods approach and shares become eligible for sale on the open market.
  • Management Changes: The resignation of Dr. Wang as CEO and executive director, and the appointment of Mr. Cai Longjun, could affect investor sentiment regarding leadership stability and strategy.
  • Reallocation of Shares: Shares from employees who left have been re-allocated, which may affect the distribution of share awards and future selling pressure.
• No Impact on Other Annual Report Information: The company confirms that aside from the clarified table, all other information in the Annual Report remains unchanged.

Detailed Table of Share Award Scheme

The corrected table now details:

• Names of grantees (directors, substantial shareholders, and other employees)
• Number of shares originally granted, adjusted for share subdivision
• Outstanding shares as of January 1, 2025, and December 31, 2025
• Vesting schedules and approximate percentage of total issued shares
• Special notes on resignations, continued consultancy, and reallocation of shares

The table highlights that the awards were granted on July 31, 2023, and details are provided for each individual grantee, including their vesting period and impact on issued share capital.

Potential Share Price Impact

• Investors should monitor the vesting schedule as significant tranches of shares could be eligible for sale, potentially impacting share price.
• Leadership changes may be scrutinized by the market, especially if key figures retain substantial share awards post-resignation.
• The correction and transparency provided by BrainAurora Medical Technology may boost investor confidence, but the underlying dilution and insider selling risks remain relevant.

Board of Directors Update

• Mr. Tan Zheng serves as Chairman and Executive Director.
• Non-executive directors: Mr. Deng Feng, Mr. Yang Fan, Ms. Wang Jingbo.
• Independent non-executive directors: Mr. Lam Yiu Por, Dr. Duan Tao, Mr. Tu Lei.

Conclusion

This announcement is potentially price sensitive due to the clarification on the large share awards to insiders, their vesting schedules, and the changes in management. Investors should pay attention to these developments as they might influence future share price movement.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult professional advisors before making any investment decisions. The author is not responsible for any losses incurred based on the information provided herein.

View BRAINAURORA-B Historical chart here